Ontology highlight
ABSTRACT: Background
Iron deficiency is a common cause of anaemia and hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in non-dialysis-dependent chronic kidney disease (ND-CKD) patients. Current intravenous iron agents cannot be administered in a single high dose because of adverse effects. Ferric carboxymaltose, a non-dextran parenteral iron preparation, can be rapidly administered in high doses.Methods
This open-label trial randomized 255 subjects with glomerular filtration rates ? 45 mL/min/1.73 m(2), haemoglobin ? 11 g/dL, transferrin saturation ? 25%, ferritin ? 300 ng/mL, and stable ESA dose to either intravenous ferric carboxymaltose 1000 mg over 15 min (with up to two additional doses of 500 mg at 2-week intervals) or oral ferrous sulphate 325 mg thrice daily for a total of 195 mg elemental iron daily for 56 days.Results
In the modified intent-to-treat population, the proportion of subjects achieving a haemoglobin increase ? 1 g/dL at any time was 60.4% with ferric carboxymaltose and 34.7% with oral iron (P < 0.001). At Day 42, mean increase in haemoglobin was 0.95 ± 1.12 vs 0.50 ± 1.23 g/dL (P = 0.005), mean increase in ferritin was 432 ± 189 ng/mL vs 18 ± 45 ng/mL (P < 0.001) and mean increase in transferrin saturation was 13.6 ± 11.9% vs 6.1 ± 8.1% (P < 0.001). Treatment-related adverse events were significantly fewer with ferric carboxymaltose than with oral iron (2.7% and 26.2%, respectively; P < 0.0001).Conclusions
We conclude that 1000 mg ferric carboxymaltose can be rapidly administered, is more effective and is better tolerated than oral iron for treatment of iron deficiency in ND-CKD patients.
SUBMITTER: Qunibi WY
PROVIDER: S-EPMC3084440 | biostudies-literature | 2011 May
REPOSITORIES: biostudies-literature
Qunibi Wajeh Y WY Martinez Carlos C Smith Mark M Benjamin Joseph J Mangione Antoinette A Roger Simon D SD
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20101007 5
<h4>Background</h4>Iron deficiency is a common cause of anaemia and hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in non-dialysis-dependent chronic kidney disease (ND-CKD) patients. Current intravenous iron agents cannot be administered in a single high dose because of adverse effects. Ferric carboxymaltose, a non-dextran parenteral iron preparation, can be rapidly administered in high doses.<h4>Methods</h4>This open-label trial randomized 255 subjects with glomerular filtration ...[more]